Whitehawk Therapeutics (NASDAQ:WHWK) Insider Bryan Ball Sells 26,389 Shares

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) insider Bryan Ball sold 26,389 shares of the firm’s stock in a transaction on Monday, April 13th. The shares were sold at an average price of $3.46, for a total transaction of $91,305.94. Following the transaction, the insider directly owned 489,566 shares of the company’s stock, valued at $1,693,898.36. The trade was a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Tuesday, April 14th, Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.64, for a total transaction of $336,554.40.
• On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total transaction of $22,624.28.
• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total transaction of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $6,070.54.

Whitehawk Therapeutics Stock Performance

WHWK stock traded down $0.10 during trading on Wednesday, hitting $3.90. 316,487 shares of the company’s stock traded hands, compared to its average volume of 187,321. Whitehawk Therapeutics, Inc. has a 52 week low of $1.39 and a 52 week high of $4.48. The business has a fifty day simple moving average of $3.40 and a 200 day simple moving average of $2.76. The stock has a market capitalization of $184.08 million, a price-to-earnings ratio of 8.30 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.21.

Institutional Investors Weigh In On Whitehawk Therapeutics

Several institutional investors have recently made changes to their positions in WHWK. Orbimed Advisors LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth about $7,915,000. Suvretta Capital Management LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth about $7,030,000. Acuta Capital Partners LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth about $6,480,000. Avoro Capital Advisors LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth about $5,414,000. Finally, KVP Capital Advisors LP bought a new stake in shares of Whitehawk Therapeutics in the 4th quarter worth about $5,242,000. Institutional investors own 52.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on WHWK. JonesTrading began coverage on shares of Whitehawk Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Wall Street Zen lowered shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Oppenheimer began coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price for the company. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.50.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.